# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Texas court rules against Humana, upholding Medicare Advantage bonus cuts and risking billions in insurer revenue tied to star ...
Wall Street edged higher Tuesday as strong bank earnings lifted sentiment, even as renewed U.S.-China trade tensions kept inves...
https://www.bloomberg.com/news/articles/2025-10-14/humana-loses-second-lawsuit-to-reverse-medicare-bonus-cuts
B of A Securities analyst Kevin Fischbeck maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $280 t...
Mizuho analyst Ann Hynes maintains Humana (NYSE:HUM) with a Outperform and raises the price target from $300 to $345.
Wells Fargo analyst Stephen Baxter maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $344 to $347.